AM23

Avacta, Aston Martin, Formula 1

[TVR5 @TVR5AVCT]

#AVCT

“We’re hoping we see something more in the
middle range of our dose levels”

[Sandy Radford @sandyradders]

Great post.

Just to tie in with your point 5, the AVA6103 trial is focused on cancers with significant unmet need.

Dr Alex Spira singled out pancreatic cancer, gastroesophageal junction cancer and colorectal cancer:

“We’ve really been devoid of new drug development.”

His closing remarks perhaps summed up his view of AVA6103:

“It’s novel compared to whatever else we’ve done, and it really focuses on some of the issues that really need to be overcome, both on drug delivery and toxicity.”

“So really excited.”

#AVCT

[AM23 @AM231982]

The AVA6000 trial is a victim of its own success in some ways, much faster trial designs using BOIN are now in use for the AVA6103 trial.

AVA6000 was the first precision drug. The evolution since for the GEN2 & GEN3 drugs is remarkable.

Look forward not back on this. Watch this from April again and again. Note they have added 2 more indications since this and are now months into the trial!

https://t.co/t4ehrgTU93

[AM23 @AM231982]

Avacta #AVCT has a very bright future.

In recent weeks they have openly compared AVA6103 preclinical data to Enhertu and Datroway both multi billion $ drugs only weeks into the actual human trial.....That is how you poke a bear!

There is a long list of positive news items coming up fast. In no particular order.

1. SGC Fast Track approval & PFS data
2. SGC commercial deal
3. First ever data on TNBC for AVA6000
4. Full AVA6000 deal
5. SAB - Representation for specialists for all the 6 indications in the AVA6103 trial
6. New Chairman
7. AVA6207 - Dual warhead deals - Multiple possible
8. Peer reviewed data
9. 5 new sites expected for AVA6103 trial just in P1A (up to 17 more to support the next stage also)
10. Bio International conference later this month.

All of these in the coming weeks are possible. It will change this company forever. Deals Deals Deals are on the menu.

[TVR5 @TVR5AVCT]

Congratulations to Richard Hughes on his appointment as Chair of #AVCT.

@TVR5AVCT looks forward to a transformative H2 under his chairmanship.

We wish Shaun Chilton all the best for the future.

[Cumulus @Cumulus51896691]

If Avacta's preCISION technology reaches 90% of solid tumours, around three quarters have no available targeted ADC treatment. Recent comparisons with Enhertu are a benchmark not a threat. preCISION drugs could treat millions without taking a single patient from them. #avct

[RAH @RAH00084]

#AVCT

[TVR5 @TVR5AVCT]

@coughlin582 of @avacta therapeutics is the obvious choice @bradloncar.

#AVCT

[AM23 @AM231982]

@GrahamHengland Indeed GRH and that opportunity has first gas in 2033......Yawn!

Guercif first gas could be late 2026 early 2027 not impossible in some form.....Always nice to have a 4000km license to work with = running room.

PG only cements his legacy when he executes commercial deals!

[RAH @RAH00084]

“Agreement on dose selection for subsequent trials” suggests #AVCT has agreed the Phase 2 AVA6000 trial design with the FDA. I.e. Project Optimus.

We have been told the 6000 will not extend beyond Phase 1b without a partner.

But have we been told they have confirmed AVA6000 trial design with FDA before today? If so, that passed me by

[TVR5 @TVR5AVCT]

It is increasingly clear #AVCT has sufficient confirmation to state they believe their Generation 2 technology is working as designed.

[AM23 @AM231982]

@KQuick20704342 I don’t see it like that Keith. Those warrants are worth £210k which is 7% of the funds which is several % too rich!

Good trade for the brokers getting paid in warrants given the massive upside. If you know you know.

[AM23 @AM231982]

New added to the clinical trials site for #AVCT in Michigan.

START Midwest is a new facility group also.

Ronan Pleass in charge.

You don't do this is AVA6103 is not performing...

That is now 3 out of 8 sites for P1A online....more to come here. Science day said 8 would support P1A and up to 20 for the next stage!

https://t.co/124ICZUfit

[Graham Harrison 🌐 @GrahamHengland]

🇲🇦

Wholly consistent re deal ✴️✴️✴️✴️✴️

🇮🇪

Bloody Nora ✴️✴️✴️✴️✴️

🇹🇹

Mighty big ✴️✴️✴️✴️✴��

[AM23 @AM231982]

@GrahamHengland

[AM23 @AM231982]

I think this is quite probable in some form...... in no particular order....

1. Naming convention of Mou6 recently dropped..suggests someone else is taking that over.

2. They had planned to drill MOU6 from the same MOU3 well pad but that has now changed to a different location perhaps more optimal factoring geology, physical space for development away from housing, nodal considerations for pipeline (if big BCF) etc

3. Multiple appraisal/ dev wells required to satisfy and stabilise flow for GSA agreements

4. EC Application being mentioned recently and you only do that if you know you can exploit the assets!

5. 10 Year tax holiday commences on EC granting therefore you want to maximise that from the get go.

6. Even if MOU3 has not cleaned up entirely you could have all the necessary kit to re-enter/ work over at the same time you drill MOU6 (a few hundred meters away) therefore activities could be performed at the same time and location cost effectively.

7. Testing on both wells would further confirm connectivity and resource in prep for another ITR...numbers go up!

8. Something clearly happened that was positive in August- Sept last year, firstly for a divestment process to be initiated and an agent to be hired! 'Pressure build up in the well is being monitored' suggesting a a degree of pressure forming at the wellhead at that time. Farm out chat was put on the back burner as a result also.

9. We have not formally been told the outcome of the pressure testing since or seen the revised ITR covering MOU3 = commercially sensitive but 100% part of deal discussions.

I could continue but won't for now..

[AM23 @AM231982]

@GrahamHengland Let me oblige you Sir!

Does this help?

A few more nodes might be very useful.

[AM23 @AM231982]

Just when you thought that was it you hear about the dual warhead AVA6207 ambitions which will no doubt be crystallising into multiple commercial deals in due course. The optionality is astounding and you don't spend time talking about AVA6207 which uses exatecan and the same warhead being used in the AVA6103 trial unless it is working!!

Congratulations to all the team.

4/4

[AM23 @AM231982]

Another outstanding Science day delivered yesterday by #AVCT to a full house of investors.

It has never been clearer that the transformational science, IP, optionality and value of the Precision platform continues to dwarf what most people can comprehend.

Focusing on a particular trial means you can easily get blinded by the lights and ignore the huge number of possibilities created by the technology which is the very foundation.

For perspective the entire ADC market was formally put on notice yesterday (again). The checkmate play has started. For all the positives ADCs have bought patients for over a decade its issues are still toxicity, tumour targeting and getting enough warhead to the tumour. The simplicity of FAP enabled Precision drugs solves all these issues in some way.

Both Enhertu and Datroway were formally compared to AVA6103 preclinical findings and got slaughtered. Blockbuster drugs generating billions today got slaughtered under that analysis! This will be peer reviewed. Replicate this in humans and the industry will wonder how little old Avacta has been hiding in plain sight for so long and hardly anyone knew!

1/4

[AM23 @AM231982]

We heard the science team talk detail for 2.5 hours. The confidence and belief they have is amazing. No ambiguity just facts represented by data, charts and numbers and rationale explanation. It is telling there is a lack of challenge to the science which is so simple and yet so extraordinary.

Chris was exceptional, lead from the front as usual and left no doubt how excited the team is for making real change here. No more compromises on enduring awful toxicity just to be treated for cancer, that is no longer good enough at Avacta and they have the answers. At some point the game will be up as the science will be supported by irrefutable clinical evidence across indications with some of the highest unmet need.

It was made crystal clear that the scope of Precision is all cancers with FAP and that is 90% of all solid tumours. They can and will have drugs in time that will be suitable to address all these indications. The scale of the opportunity and the TAM is biblical. Although this is not new thinking about this again in the context of what we were told yesterday only confirms this is the expectation not just a pipe dream.

3/4